SCLX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
SCLX Current Performance
-1.18%
Scilex holding co
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to SCLX
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
CELU | Celularity inc | 1 | 2 | 2 | 1 | 1 | |
ARTL | Artelo biosciences inc | 3 | 3 | 4 | 1 | 1 | |
CYTK | Cytokinetics, inc. | 3 | 3 | 5 | 3 | 1 | |
JSPR | Jasper therapeutics inc | 1 | 3 | 2 | 3 | 1 | |
ZVRA | Zevra therapeutics inc | 2 | 4 | 2 | 2 | 1 |
- CELU Celularity incValue 1Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
SCLX Profile
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.